🏛️ Verified NIH Record • Updated 2026-03-04
A Community-Based Screening Program to Identify Participants at High Risk for Amyloid Pathology (NCT06043700)
A Community-Based Screening Program to Identify, Using Blood-Based Biomarkers, Individuals With or Without Alzheimer's Disease Symptoms Who Are at High Risk for Brain Amyloid Pathology
🔵 Active, Not Recruiting Interventional Protocol 📊 Observational Clinical Research Sponsor: Eisai Limited
🩺 Plain-English Summary (8th-Grade Level)
The primary purpose of this study is to identify participants with or without symptoms of Alzheimer's Disease (AD) that are at high risk for brain amyloid pathology using blood-based biomarkers.
Who can join: Review the eligibility criteria below.
Location: Eisai Site #3 — Clermont, Florida
Age range: 50 Years to 80 Years
🧪 Interventions in This Study
- No Intervention (OTHER)
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (3 Sites)
- Eisai Site #3 — Clermont, Florida
- Eisai Site #1 — Lady Lake, Florida
- Eisai Site #2 — District Heights, Maryland
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Alzheimer's Disease
- Standardizing Care for Neuropsychiatric Symptoms and Quality of Life in Dementia — Calgary, Alberta
- A Study of E2814 With Concurrent Lecanemab Treatment in Participants With Early Alzheimer's Disease — Phoenix, Arizona
- DIAN-TU Amyloid Removal Trial (ART) in Dominantly Inherited Alzheimer's Disease — Birmingham, Alabama
- A Study of Remternetug (LY3372993) in Early Alzheimer's Disease (TRAILRUNNER-ALZ 3) — Birmingham, Alabama
- A Study of Different Donanemab (LY3002813) Dosing Regimens in Adults With Early Alzheimer's Disease (TRAILBLAZER-ALZ 6) — Chandler, Arizona
Explore by condition: All Alzheimer's Disease clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.